The February 10, 2016, article by Hortobagyi et al entitled “Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2” (J Clin Oncol 34:419-426, 2016) was published online October 26, 2015, with errors in the AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.
Dr. Baselga’s COIs were given as:
José Baselga
Honoraria: Novartis, Infinity
Consulting or Advisory Role: Novartis, Verastem, Infinity
They should have read as:
José Baselga
Leadership: Infinity Pharmaceuticals, Aura Biosciences
Stock or Other Ownership: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Aura Biomedical, Apogen, Seragon, Aragon, Verastem
Honoraria: Infinity Pharmaceuticals, PMV Pharma, Juno Therapeutics, GRAIL, Seragon
Consulting or Advisory Role: Novartis, Eli Lilly, GRAIL, AstraZeneca
Research Funding: Roche/Genentech
Travel, Accommodations, Expenses: Roche/Genentech
This has been corrected as of January 11, 2019. The author apologizes for the errors.